Methylprednisolone Following Minimally Invasive Lumbar Decompression: A Large Prospective Single-Institution Study

T J Florence1, Irene Say2, Joshua Rivera3

  • 1UCLA Neurosurgery, Los Angeles, CA.

Spine
|April 24, 2023
PubMed
Abstract

Insights

Intraoperative methylprednisolone may offer a temporary disability reduction for spinal surgery patients with high preoperative Oswestry Disability Index (ODI) scores, but shows no pain improvement or long-term benefits.

Area of Science:

  • Neurosurgery
  • Spinal Surgery
  • Minimally Invasive Spine Surgery

Background:

  • Intraoperative methylprednisolone is frequently used after microscopic laminectomy/microdiscectomy to reduce neural element irritation.
  • Existing data on its efficacy is inconsistent, with some studies suggesting increased complication risks and limited follow-up.
  • Previous research has yielded equivocal effects on pain and disability, necessitating further investigation.

Purpose of the Study:

  • To evaluate the clinical effectiveness of intraoperative epidural methylprednisolone instillation following microscopic laminectomy/microdiscectomy.
  • To assess the impact of intraoperative steroids on pain, disability, complications, and reoperation rates.

Main Methods:

  • A multiyear prospective study was conducted from 2013 to 2019, involving 486 patients undergoing minimally invasive spine decompressions.
  • Patients were divided into groups receiving or not receiving intraoperative steroids.
  • Primary outcomes included pain (Visual Analog Scale) and disability (Oswestry Disability Index) at 2 weeks and 4 months; secondary outcomes were complications, readmissions, and reoperations.

Main Results:

  • No significant difference in pain reduction was observed between groups at 2 weeks or 4 months.
  • A transient reduction in disability (ODI) was noted at 2 weeks in the steroid group, primarily in patients with high preoperative ODI.
  • Patients receiving steroids were more likely to undergo revision spinal surgery during the follow-up period (mean 5.17 years).

Conclusions:

  • Intraoperative methylprednisolone provides a significant, albeit temporary, reduction in disability for patients with high preoperative ODI.
  • The procedure does not demonstrate a measurable effect on pain levels.
  • Given the transient benefits and equivocal impact on reoperation risk, its use may be best limited to patients with substantial preoperative disability.